Filtered By:
Drug: SGLT2 Inhibitors

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
CONCLUSION: Use of SGLT2 inhibitors versus GLP-1 RAs was associated with consistent reductions in HHF risk among T2D patients with and without CVD, although the absolute benefit was greater in patients with CVD. There were no large differences in risk for MI or stroke among T2D patients with and without CVD.PRIMARY FUNDING SOURCE: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.PMID:34570599 | DOI:10.7326/M21-0893
Source: Annals of Internal Medicine - September 27, 2021 Category: Internal Medicine Authors: Elisabetta Patorno Phyo T Htoo Robert J Glynn Sebastian Schneeweiss Deborah J Wexler Ajinkya Pawar Lily G Bessette Kristyn Chin Brendan M Everett Seoyoung C Kim Source Type: research

Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
ConclusionsThere were no demonstrable treatment differences across SGLT2 inhibitors across cardiovascular, renal, and metabolic outcomes, although this needs to be interpreted considering the wide confidence intervals, limited number of included studies, and heterogeneity present. Future research of different SGLT2 inhibitors in head-to-head studies is warranted to determine if there is a drug class effect.
Source: European Journal of Clinical Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Source Type: research

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
In 2015, the EMPA-REG OUTCOME trial reported that treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, significantly reduced the risk of the primary composite outcome – death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk [1]. Since that landmark trial, many other large randomised controlled trials (RCTs) have confirmed the cardiovascular (particularly with respect to he art failure) and renal benefits of this drug class [2–7].
Source: Diabetes Research and Clinical Practice - September 2, 2021 Category: Endocrinology Authors: Tamara Y. Milder, Sophie L. Stocker, Melissa Baysari, Richard O. Day, Jerry R. Greenfield Source Type: research

Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review
Cardiovasc Hematol Agents Med Chem. 2021 Aug 9. doi: 10.2174/1871525719666210809121016. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-diabetic agents that block the reabsorption of glucose in the proximal convoluted tubule of the nephron, thereby contributing to glycosuria and lowering blood glucose levels. SGLT2 inhibitors have been associated with improved cardiovascular outcomes in patients with diabetes, including a reduced risk of cardiovascular death and hospitalizations for heart failure. Recently, DAPA-HF and EMPEROR REDUCED trials showed the beneficial cardiova...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - August 9, 2021 Category: Cardiology Authors: Mauro Gitto Dimitrios A Vrachatis Gianluigi Condorelli Konstantinos Papathanasiou Bernhard Reimers Spyridon Deftereos Giulio G Stefanini Source Type: research

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
AbstractSotagliflozin is a dual sodium-glucose co-transporter (SGLT) 2 inhibitor, manifesting a 20-fold higher inhibitory activity for SGLT2 than for SGLT1. Differences in SGLT2 over SGLT1 selectivity of the available agents have been proposed to relate to variability in efficacy and safety characteristics. In contrast to other SGLT2  inhibitors, the cardiorenal effects of sotagliflozin in type 2 diabetes had not been explored until recently, when the results of SOLOIST-WHF (focusing on heart failure [HF] outcomes) and SCORED (focusing on renal outcomes) were published. In SOLOIST-WHF, sotagliflozin reduced the risk of th...
Source: Drugs - August 1, 2021 Category: Drugs & Pharmacology Source Type: research

Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials
Conclusions: This updated network meta-analysis reproduced the findings in the first network meta-analysis, and moreover revealed that sotagliflozin was one of the most effective drugs as for lowering MI, stroke, MACE, and HHF, whereas ertugliflozin was not. These findings will provide the according evidence regarding the usage of specific SGLT2 inhibitors and GLP-1 RAs in T2D patients for prevention of specific cardiorenal endpoints.
Source: Medicine - July 30, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
AbstractSotagliflozin is a dual sodium-glucose co-transporter (SGLT) 2 inhibitor, manifesting a 20-fold higher inhibitory activity for SGLT2 than for SGLT1. Differences in SGLT2 over SGLT1 selectivity of the available agents have been proposed to relate to variability in efficacy and safety characteristics. In contrast to other SGLT2  inhibitors, the cardiorenal effects of sotagliflozin in type 2 diabetes had not been explored until recently, when the results of SOLOIST-WHF (focusing on heart failure [HF] outcomes) and SCORED (focusing on renal outcomes) were published. In SOLOIST-WHF, sotagliflozin reduced the risk of th...
Source: Drugs - July 7, 2021 Category: Drugs & Pharmacology Source Type: research

Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
ConclusionsThere were no demonstrable treatment differences across SGLT2 inhibitors across cardiovascular, renal, and metabolic outcomes, although this needs to be interpreted considering the wide confidence intervals, limited number of included studies, and heterogeneity present. Future research of different SGLT2 inhibitors in head-to-head studies is warranted to determine if there is a drug class effect.
Source: European Journal of Clinical Pharmacology - May 3, 2021 Category: Drugs & Pharmacology Source Type: research

Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?
We have read with great interest a study of meta-analysis1 recently published in Journal of Stroke and Cerebrovascular Diseases. In that study1 Barkas and colleagues drew their main conclusion that sodium-glucose transporter 2 (SGLT2) inhibitors reduce the risk of total stroke in patients with type 2 diabetes mellitus (T2DM) and impaired renal function (IRF), which was based on the result of meta-analysis on the outcome of total stroke (including ischemic and hemorrhagic stroke) in the subgroup of patients with T2DM and IRF (Fig.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2021 Category: Neurology Authors: Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu Tags: Letter to the Editor Source Type: research